BioPharma Resources

Drug Trial Radar · NCT05064059

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

A Phase 3 Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (KEYFORM-007)

Last checked: Nov 19, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 441 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

441

Actual

Start

Nov 10, 2021

Primary completion

Aug 15, 2024

Study completion Feb 21, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic colorectal cancer. The study will also compare MK-4280A with the standard of care treatment of regorafenib and TAS-102 (trifluridine and tipiracil). The primary study hypothesis is that coformulated favezelimab/pembrolizumab (MK-4280A) is superior to standard of care with respect to overall survival.

Conditions

  • Colorectal Cancer

Interventions

  • favezelimab/pembrolizumabBiological

    Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion

  • regorafenibDrug

    Oral

  • TAS-102Drug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 33 months

Locations

152 sites in 21 countries. Site status is shown where the registry gives one.

  • Georgetown University Hospital ( Site 1148)

    Washington D.C., District of Columbia

  • Sibley Memorial Hospital ( Site 1143)

    Washington D.C., District of Columbia

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1118)

    Marietta, Georgia

  • Norton Cancer Institute ( Site 1139)

    Louisville, Kentucky

  • Rutgers Cancer Institute of New Jersey ( Site 1105)

    New Brunswick, New Jersey

  • Memorial Sloan Kettering Cancer Center ( Site 1703)

    New York, New York

  • Oregon Health & Science University ( Site 1141)

    Portland, Oregon

  • MUSC Hollings Cancer Center ( Site 1715)

    Charleston, South Carolina

  • The West Clinic, PLLC dba West Cancer Center ( Site 1149)

    Germantown, Tennessee

  • UT Southwestern Medical Center ( Site 1709)

    Dallas, Texas

  • Intermountain Medical Center ( Site 1707)

    Murray, Utah

  • Inova Schar Cancer Institute ( Site 1130)

    Fairfax, Virginia

  • VCU Health Adult Outpatient Pavillion ( Site 1712)

    Richmond, Virginia

  • Blue Ridge Cancer Care ( Site 1718)

    Roanoke, Virginia

  • Seattle Cancer Care Alliance ( Site 1107)

    Seattle, Washington

  • Westmead Hospital ( Site 0057)

    Westmead, New South Wales, Australia

  • Royal Brisbane and Women s Hospital ( Site 0058)

    Herston, Queensland, Australia

  • Queen Elizabeth Hospital ( Site 0050)

    Woodville South, South Australia, Australia

  • Frankston Hospital ( Site 0056)

    Frankston, Victoria, Australia

  • Western Health-Sunshine & Footscray Hospitals ( Site 0052)

    St Albans, Victoria, Australia

  • St John of God Subiaco Hospital ( Site 0051)

    Perth, Western Australia, Australia

  • London Regional Cancer Program - London HSC ( Site 0154)

    London, Ontario, Canada

  • The Ottawa Hospital ( Site 0151)

    Ottawa, Ontario, Canada

  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0155)

    Toronto, Ontario, Canada

  • Centro Investigacion Cancer James Lind ( Site 0204)

    Temuco, Araucania, Chile

  • IC La Serena Research ( Site 0202)

    La Serena, Coquimbo Region, Chile

  • Clinica Puerto Montt ( Site 0211)

    Port Montt, Los Lagos Region, Chile

  • Fundacion Arturo Lopez Perez FALP ( Site 0208)

    Santiago, Region M. de Santiago, Chile

  • Oncovida ( Site 0209)

    Santiago, Region M. de Santiago, Chile

  • Clínica Vespucio ( Site 0205)

    Santiago, Region M. de Santiago, Chile

  • Pontificia Universidad Catolica de Chile ( Site 0206)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill ( Site 0200)

    Santiago, Region M. de Santiago, Chile

  • The Second Affiliated Hospital of Anhui Medical University ( Site 1179)

    Hefei, Anhui, China

  • Chongqing Cancer Hospital ( Site 1151)

    Chongqing, Chongqing Municipality, China

  • Fujian Province Cancer Hospital ( Site 1178)

    Fuzhou, Fujian, China

  • Sun Yat-Sen University Cancer Center ( Site 1150)

    Guangzhou, Guangdong, China

  • Southern Medical University Nanfang Hospital ( Site 1154)

    Guangzhou, Guangdong, China

  • The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 1159)

    Guangzhou, Guangdong, China

  • Guangxi Medical University Affiliated Tumor Hospital ( Site 1158)

    Nanning, Guangxi, China

  • Hainan General Hospital ( Site 1177)

    Haikou, Hainan, China

Showing 40 of 152 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.